Niche Oxygen Wound Unique FDA approved wound dressing delivering continuous pure oxygen for up to five days positions the company in a differentiated niche with strong potential in hospitals and urgent care centers seeking faster wound healing and reduced pain.

Clinical Validation Multiple clinical trials at major institutions and Army research show accelerated healing and lower pain with OxyBand, providing compelling evidence to support outreach to burn centers, trauma clinics, and dermatology departments.

Strategic Partnerships Target collaboration with burn units, orthopedic wound teams, and regenerative medicine researchers could expand adoption; potential for co‑development with medical distributors serving rural or military healthcare facilities.

Expansion via Public Sector Demonstrated military trial results suggest government and defense medical program opportunities, including procurement through military and VA channels, where wound care innovations are prioritized.

Low Revenue Scale Current revenue under one million with a $700k funding runway indicates a need for rapid sales acceleration through focused pilots, clinical adoption playbooks, and early adopter clinics to build scalable volume.